- (-%)
Source:
Qsam Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. Our initial technology is Samarium-153 DOTMP, a/k/a CycloSam, a clinical-stage bone targeting radiopharmaceutical.
Country | United States |
Headquarters | austin, texas |
Phone Number | 512-343-4558 |
Industry | manufacturing |
CEO | Douglas Baum |
Website | www.qsambio.com |